Email updates

Keep up to date with the latest news and content from Journal of Hematology & Oncology and BioMed Central.

Open Access Case report

Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report

Jun Wang1, George W Saukel1, Carlos A Garberoglio2, Wichit Srikureja3 and Chung-Tsen Hsueh4*

Author Affiliations

1 Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA

2 Department of General and Trauma Surgery, Loma Linda University Medical Center, Loma Linda, CA 92354, USA

3 Division of Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA

4 Division of Medical Oncology and Hematology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA

For all author emails, please log on.

Journal of Hematology & Oncology 2010, 3:31  doi:10.1186/1756-8722-3-31

Published: 9 September 2010

Abstract

We report a 49-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen. He underwent esophagogastroduodenoscopy in September 2009, which revealed a 2-cm gastric ulcer on the lesser curvature proximal to angularis. Biopsy of gastric ulcer showed moderately differentiated adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry and fluorescence in situ hybridization. Further workups with endoscopic ultrasound, computed tomography and positron emission tomography staged his cancer as T3N1M0. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab, oxaliplatin, docetaxel and capecitabine without severe toxicities except grade 2 diarrhea near the completion of cycle 3 requiring discontinuation of capecitabine. Afterwards, he received total gastrectomy with extended D2 lymph node dissections showing pathological complete response. He went on to receive 3 more cycles of chemotherapy postoperatively. The role of trastuzumab as a part of perioperative therapy in gastric cancer overexpressing HER2 is worth further investigation.